Core Insights - The development of acne vaccines represents a shift from symptomatic treatment to immune-targeted therapy, with the first therapeutic acne vaccine in China receiving clinical trial approval [1][3] - Acne affects over 9.4% of the global population, with a prevalence rate of 8.1% in China, indicating a significant market potential for innovative treatments [1][2] Treatment Landscape - Current acne treatments include topical antibiotics, retinoids, and physical or chemical therapies, each with limitations such as antibiotic resistance and side effects [2] - Recent advancements in understanding the immune and inflammatory factors behind acne have opened up possibilities for etiological treatment and disease prevention [2] Vaccine Development - Various companies are exploring acne vaccines, including Sanofi's mRNA vaccine and a candidate from the University of California, San Diego, targeting hyaluronidase to prevent acne [2][3] - The consensus in the industry is that the main triggers for acne are follicular hyperkeratinization and increased sebum secretion driven by androgens [3] Market Potential - The global acne treatment market is projected to grow from $9.9 billion in 2022 to $17.5 billion by 2032, with a compound annual growth rate (CAGR) of 5.86% [4] - Price considerations will be crucial for the initial promotion of acne vaccines, but their cost-effectiveness may improve as technology matures and clinical data supports efficacy [4]

经济观察网 据威斯克生物微信公众号消息，近日，由威斯克生物联合四川大学华西医院自主研发的痤 疮治疗性疫苗，正式获得中国国家药品监督管理局（NMPA）新药临床试验申请（IND）批准，成为我 国首款进入临床阶段的痤疮治疗性疫苗。威斯克生物是一家创新型生物医药企业，2021—2025年连续四 年成功入选独角兽企业，在北京、成都和广州设立了研发、生产和销售机构。 ...